Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Humacyte (NASDAQ:HUMA) announced its quarterly earnings data on Tuesday. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04, FiscalAI reports. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.77 million.

Here are the key takeaways from Humacyte’s conference call:

• Symvess sales and hospital adoption accelerated: Third-quarter sales rose 151% sequentially to just over $1 million, with 49 hospitals ordering by quarter-end, up from 34. October sales reached $800,000, and management expects fourth-quarter sales to at least double Q3.
• Humacyte plans to submit its dialysis-access sBLA later this month, supported by three Phase III studies. The FDA’s review designation is not yet known: management outlined a potential launch around June 2027 with priority review, or after September without it.
• The company initiated its first-in-human Phase IIa study of its coronary tissue-engineered vessel for bypass surgery and is screening patients; it has also completed the first commercial-scale manufacturing lot for the product.
• Humacyte reported a Q3 net loss of $15.5 million and $15.0 million in operating cash use, although cash, cash equivalents, and restricted cash totaled $64.9 million at quarter-end. Cost of goods sold was $1.4 million against $1 million in sales, largely reflecting underused production capacity, which management expects to continue affecting Q4.

Humacyte Stock Performance

HUMA traded up $0.11 during trading on Tuesday, hitting $0.57. The stock had a trading volume of 9,327,904 shares, compared to its average volume of 7,551,102. The company has a 50 day simple moving average of $0.49 and a 200-day simple moving average of $0.79. The firm has a market cap of $157.23 million, a PE ratio of -1.15 and a beta of 2.64. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07. Humacyte has a 12 month low of $0.34 and a 12 month high of $1.52.

Wall Street Analyst Weigh In

HUMA has been the topic of a number of research analyst reports. Wall Street Zen cut Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Benchmark decreased their target price on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research note on Thursday, August 13th. Barclays raised Humacyte to a “hold” rating in a research note on Wednesday, October 7th. BTIG Research reiterated a “buy” rating and set a $2.00 price objective on shares of Humacyte in a research note on Tuesday. Finally, Williams Trading set a $1.00 price target on shares of Humacyte in a research note on Friday, October 16th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.96.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient.

Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.